Lead Product(s) : Ribaxamase
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Theriva™ Biologics Sees Positive DSMC Review of SYN-004 in Transplant Recipients
Details : SYN-004 (ribaxamase) is an oral prophylactic therapy designed to degrade certain IV beta-lactam antibiotics. It is being evaluated in allogeneic HCT recipients for the prevention of aGVHD.
Product Name : SYN-004
Product Type : Enzyme
Upfront Cash : Inapplicable
March 10, 2024
Lead Product(s) : Ribaxamase
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ribaxamase,Cefepime
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SYN-004 (ribaxamase) is designed to degrade certain IV beta-lactam antibiotics within the GI tract and maintain the natural balance of the gut microbiome for the prevention of CDI, overgrowth of pathogenic organisms and aGVHD in allogeneic HCT recipients...
Product Name : SYN-004
Product Type : Enzyme
Upfront Cash : Inapplicable
February 16, 2023
Lead Product(s) : Ribaxamase,Cefepime
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ribaxamase,Cefepime
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SYN-004 (ribaxamase) is an oral prophylactic therapy designed to maintain the natural balance of the gut microbiome for the prevention of CDI, overgrowth of pathogenic organisms, the emergence of AMR and aGVHD in allogeneic HCT recipients.
Product Name : SYN-004
Product Type : Enzyme
Upfront Cash : Inapplicable
September 27, 2022
Lead Product(s) : Ribaxamase,Cefepime
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ribaxamase,Meropenem
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SYN-004 (ribaxamase), is an oral prophylactic therapy designed to degrade certain IV beta-lactam antibiotics within GI tract, thereby preventing antibiotic-mediated damage to the gut microbiome and reducing adverse outcomes associated with antibiotic-med...
Product Name : SYN-004
Product Type : Enzyme
Upfront Cash : Inapplicable
March 11, 2022
Lead Product(s) : Ribaxamase,Meropenem
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ribaxamase
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The phase 1b/2a study will comprise a single center, randomized, double-blinded, placebo-controlled clinical trial of oral SYN-004 (ribaxamase) in up to 36 evaluable adult allogeneic HCT recipients.
Product Name : SYN-004
Product Type : Enzyme
Upfront Cash : Inapplicable
July 01, 2020
Lead Product(s) : Ribaxamase
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable